Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Renal impairment in type 2 diabetes limits available glucose-lowering treatment options. This trial was conducted to establish the efficacy and safety of liraglutide as an add-on to existing glucose-lowering medications in patients with inadequately controlled type 2 diabetes and moderate renal impairment. RESEARCH DESIGN AND METHODS: In this 26-week, double-blind trial, 279 patients with HbA1c 7–10%, BMI 20–45 kg/m2, and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2; MDRD) were randomized (1:1) to once-daily liraglutide 1.8 mg (n = 140) or placebo (n = 139). RESULTS: The estimated treatment difference in HbA1c from baseline to week 26 was −0.66% (−7.25 mmol/mol) (95% CI −0.90 to −0.43 [−9.82 to −4.69]), P < 0.0001). Fasting plasma glucose decreased more with liraglutide (−1.22 mmol/L [−22.0 mg/dL]) than with placebo (−0.57 mmol/L [−10.3 mg/dL], P = 0.036). There was a greater reduction in body weight with liraglutide (−2.41 kg) than with placebo (−1.09 kg, P = 0.0052). No changes in renal function were observed (eGFR relative ratio to baseline: −1% liraglutide, +1% placebo; estimated treatment ratio [ETR] 0.98, P = 0.36). The most common adverse events were gastrointestinal (GI) adverse effects (liraglutide, 35.7%; placebo, 17.5%). No difference in hypoglycemic episodes was observed between treatment groups (event rate/100 patient-years of exposure: liraglutide, 30.47; placebo, 40.08; P = 0.54). The estimated ratio to baseline for lipase was 1.33 for liraglutide and 0.97 for placebo (ETR 1.37, P < 0.0001). CONCLUSIONS: Liraglutide did not affect renal function and demonstrated better glycemic control, with no increase in hypoglycemia risk but with higher withdrawals due to GI adverse events than placebo in patients with type 2 diabetes and moderate renal impairment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike the LEADER and SCALE trials, in the LIRA-RENAL trial liraglutide was found to be ineffective in improving renal outcomes in a sample of 279 diabetic patients with moderate CKD (eGFR 30–59 mL/min/1.73 m2).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
In the citing paper
“The authors found no difference in terms of eGFR and UACR compared with placebo after 26 weeks of treatment [44].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
Citations
Cites
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725 · cited 1×
“Safety assessments included adverse events (AEs), change from baseline to Week 26 in renal function (eGFR [MDRD] (19), urinary albumin:creatinine ratio [UACR]), amylase, lipase and pulse rate.”
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 1×
“Albuminuria is not only a marker for kidney damage but it is also a cardiovascular risk factor (33,34).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700 · cited 1×
“glucagon-like peptide 1 (GLP-1) analog (13), is completely metabolized through a proteolytic mechanism and is not predominantly eliminated by a single organ (14).”
BackgroundKohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652 · cited 2×
“This 26-week randomized, double-blind, placebo-controlled, parallel-group trial was conducted between June 2012 and August 2013 and included patients from 78 sites: France (4 sites), Poland (8), Russian Federation (15), Ukraine (6), UK (9), USA (36).”
BackgroundFrequency of hypoglycemia and its significance in chronic kidney disease
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., & Fink, J. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00800209 · Cited by 423 · cited 1×
“Patients with chronic kidney disease and diabetes are at increased risk of hypoglycemia, particularly when using insulin (35).”
BackgroundHypoglycemia in patients with type 2 diabetes mellitus
Miller, C. D., Phillips, L. S., Ziemer, D. C., Gallina, D. L., Cook, C. B., & El-Kebbi, I. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1653 · Cited by 341
Epidemiology of Diabetic Kidney Disease
Reutens, A. T. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.001 · Cited by 326 · cited 1×
“In the UK Prospective Diabetes Study (UKPDS), 28% of patients with type 2 diabetes developed renal impairment after amedian of 15 years after the diagnosis of diabetes (3).”
BackgroundThe renal metabolism of insulin
Rabkin, R., Ryan, M. P., & Duckworth, W. C. (1984) · Diabetologia · doi:10.1007/bf00304849 · Cited by 295 · cited 1×
“Pharmacokinetic aspects of drugs cleared by the kidney can be influenced by renal impairment leading to the cessation or dosage reduction in many glucoselowering therapies (5-8) that may have reduced tolerability or increased safety risk in this population (9-12).”
BackgroundChanges in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease
Schmieder, R. E., Mann, J. F. E., Schumacher, H., Gao, P., Mancia, G., Weber, M. A., McQueen, M., Koon, T., & Yusuf, S. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010091001 · Cited by 270 · cited 1×
“Albuminuria is not only a marker for kidney damage but is also a cardiovascular risk factor (33,34).”
BackgroundSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
Chan, J. C. N., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & Williams‐Herman, D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00914.x · Cited by 238 · cited 3×
“This 26-week, randomized, double-blind, placebo-controlled, parallel-group trial was conducted between June 2012 and August 2013 and included patients from 78 sites: France (4 sites), Poland (8 sites), Russian Federation (15 sites), Ukraine (6 sites), U.K. (9 sites), and U.S. (36 sites).”
BackgroundSelf-citationEffect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03536.x · Cited by 215 · cited 1×
“75 mg subcutaneously) pharmacokinetic trial with liraglutide provided initial evidence that the exposure to liraglutide was not increased in patients with all stages of renal impairment relative to patients with normal renal function (15).”
BackgroundMcGill, J. B., Sloan, L., Newman, J., Patel, S., Sauce, C., von Eynatten, M., & Woerle, H.-J. (2013) · Diabetes Care · doi:10.2337/dc12-0706 · Cited by 204
Malm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034066 · Cited by 201
Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease
Krepinsky, J. C., Ingram, A. J., & Clase, C. M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70204-6 · Cited by 120 · cited 1×
“Pharmacokinetic aspects of drugs cleared by the kidney can be influenced by renal impairment leading to the cessation or dosage reduction in many glucoselowering therapies (5-8) that may have reduced tolerability or increased safety risk in this population (9-12).”
BackgroundLando, H. M., Alattar, M., & Dua, A. P. (2012) · Endocrine Practice · doi:10.4158/ep11290.or · Cited by 102
Investigation of Exenatide Elimination and Its In Vivo and In Vitro Degradation
Copley, K., McCowen, K., Hiles, R., Nielsen, L., Young, A., & Parkes, D. (2006) · Current Drug Metabolism · doi:10.2174/138920006776873490 · Cited by 100 · cited 1×
“Like liraglutide, albiglutide is degraded by enzymatic catabolism (23) whereas exenatide (24) and lixisenatide (25) are eliminated by renal clearance.”
BackgroundLeiter, L. A., Carr, M. C., Stewart, M. W., Jones-Leone, A. R., Scott, R., Yang, F., & Handelsman, Y. (2014) · Diabetes Care · doi:10.2337/dc13-2855 · Cited by 97 · cited 2×
“73m(2)) (23) demonstrated that once-weekly albiglutide was more efficacious than sitagliptin.”
BackgroundGiorda, C. B., Nada, E., & Tartaglino, B. (2014) · Endocrine · doi:10.1007/s12020-014-0179-0 · Cited by 89
Mild Renal Impairment and the Efficacy and Safety of Liraglutide
Davidson, J. A., Brett, J., Falahati, A., & Scott, D. (2010) · Endocrine Practice · doi:10.4158/ep10215.or · Cited by 88
Self-citationSteinberg, W. M., Nauck, M. A., Zinman, B., Daniels, G. H., Bergenstal, R. M., Mann, J. F. E., Ravn, L. S., Moses, A. C., Stockner, M., Baeres, F. M. M., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000229 · Cited by 88 · cited 2×
“Results (LEADER) trial, 24% of patients (n=1840) with moderate renal impairment and 12% of the patients (n=3417) with normal eGFR demonstrated elevated lipase levels at baseline (37).”
BackgroundDavies, M. J., Kela, R., & Khunti, K. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 68
Self-citationSchweizer, A., & Dejager, S. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0027-x · Cited by 29 · cited 1×
“Pharmacokinetic aspects of drugs cleared by the kidney can be influenced by renal impairment leading to the cessation or dosage reduction in many glucoselowering therapies (5-8) that may have reduced tolerability or increased safety risk in this population (9-12).”
BackgroundSteinberg, W. M., DeVries, J. H., Wadden, T. A., Jensen, C. B., Svendsen, C. B., & Rosenstock, J. (2012) · Gastroenterology · doi:10.1016/s0016-5085(12)63296-x · Cited by 26 · cited 2×
“Lipase levels are elevated in;20% of patients with type 2 diabetes (36).”
BackgroundResultAchieving glycemic control in patients with type 2 diabetes and renal impairment
Avogaro, A., & Schernthaner, G. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0442-x · Cited by 21 · cited 2×
“Impaired renal function is associated with increased cardiovascular risk which is further increased by poor glycemic control (1,4).”
BackgroundMetformin use in chronic kidney disease: new evidence to guide dosing
Herrington, W. G., Nye, H. J., & Aung, T. (2013) · QJM · doi:10.1093/qjmed/hct155 · Cited by 13 · cited 1×
“Pharmacokinetic aspects of drugs cleared by the kidney can be influenced by renal impairment leading to the cessation or dosage reduction in many glucoselowering therapies (5-8) that may have reduced tolerability or increased safety risk in this population (9-12).”
BackgroundLixisenatide: clinical profile and available evidence
Dicembrini, I., Bigiarini, M., & Mannucci, E. (2013) · Diabetes Management · doi:10.2217/dmt.13.64 · Cited by 3 · cited 1×
“Like liraglutide, albiglutide is degraded by enzymatic catabolism (23) whereas exenatide (24) and lixisenatide (25) are eliminated by renal clearance.”
Background
Research works printed but not linked: 1
- Scott, 2014, Efficacy and safety of liraglutide versus placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial (Abstract), J Am Soc Nephrol, 25, 75A
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationMolecular mechanisms of ROS production and oxidative stress in diabetes
Newsholme, P., Cruzat, V. F., Keane, K. N., Carlessi, R., & de Bittencourt, P. I. H. (2016) · Biochemical Journal · doi:10.1042/bcj20160503c · Cited by 878
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
“13,14 Alternatively, differences between the results in this trial and the encouraging earlier study using recombinant GLP-17 could be due to the cardioprotective roles of GLP-1 metabolites, such as GLP-1(9-36)amide, which act independently of the GLP-1 receptor and are not generated by GLP-1 agonists like liraglutide.”
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Metadata
- Authors
- Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E.
- Affiliations
- University of Leicester (GB)
- Swansea University (GB)
- Weill Cornell Medical College in Qatar (QA)
- Steno Diabetes Center, Gentofte, Denmark
- Clinical Research Development Associates, Rosedale, NY
- Department of Diabetic Nephropathy, Endocrinology Research Centre, Moscow, Russia
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Emory University (US)
- Corresponding author
- Davies, Melanie J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-12-17
- Volume
- 39
- Issue
- 2
- Pages
- 222-230
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2236659707
- Cited by
- 235
- References
- 35
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 17 · 2023: 28 · 2022: 18 · 2021: 19 · 2020: 24 · 2019: 22 · 2018: 28 · 2017: 24 · 2016: 16
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, type 2 diabetes, renal dysfunction, glycemic control, HbA1c, fasting blood glucose, weight loss, renal function, lipase, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Gastrointestinal Tract, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.